S&P 500 Analysis & ETF Trading

[kiy]

TTNP...Pharma...develops products based on ProNeura, a proprietary long-term drug delivery technology that focuses primarily on treatments for chronic diseases, such as Parkinson's disease. The company offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the medicine buprenorphine in patients for six months following a single treatment. It is also developing ProNeura-Ropinirole, an implant to provide long-term delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; ProNeura-Triiodothyronine, an implant to provide long-term delivery of triiodothyronine for the treatment of hypothyroidism; and Fanapt, an atypical antipsychotic for the treatment of schizophrenia.






TTNP Pharma...primarily on treatments for chronic diseases, such as Parkinson's disease. The company offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the medicine buprenorphine in patients for six months following a single treatment.